Summary:
An Oral Option to Treat AD Could Be on the Horizon
The BroADen Study is looking for adults 18–55 to join in on research for a once-daily oral study drug that may help reduce the symptoms of atopic dermatitis (AD). This research is evaluating if the investigational study drug is safe and how it works in adults with moderate to severe AD (eczema).